康寧傑瑞(9966.HK)首日上市高開27.45%
格隆匯12月12日丨康寧傑瑞(9966.HK)今日首日上市高開27.45%,開報13港元,盤前成交5.75億港元,最新總市值117億港元。該股發行價10.2港元(發行區間上限定價),認購倍數192.1倍。
康寧傑瑞的基石投資者包括OrbiMed、Greenwoods、清池資本、摩根士丹利、泰康人壽、Matthews、綠葉製藥七家公司。公司是一家臨牀階段生物製藥公司,在雙特異性及蛋白質工程方面擁有全面整合的專有生物製劑平台。公司研發進程最快的產品是合作開發的抗PD-L1單抗KN035,該產品可能成為全球第一個可皮下注射的PD-L1抑制劑,而旗艦產品KN035是一種雙特異性抗體(BsAb)免疫檢查點抑制劑,可能成為全球首個同時針對兩個經過臨牀驗證的免疫檢查點PD-L1及CTLA-4的雙特異性抗體(BsAb)藥物。
不過值得注意的是,康寧傑瑞並未從產品銷售中獲得任何收入,同時該企業也判斷產品銷售在短期內不會產生收入,2019年前六個月研發開支已達到5580萬元,較2017、2018年快速上升,考慮到未來新增的臨牀試驗投入,未來研發開支仍會持續上升,集團虧損情況也仍將持續。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.